Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://persianstar.ir
Are you over 18 and want to see adult content?
A complete backup of https://pocketbook.ua
Are you over 18 and want to see adult content?
A complete backup of https://planetatangerina.com
Are you over 18 and want to see adult content?
A complete backup of https://afp.gov.au
Are you over 18 and want to see adult content?
A complete backup of https://pa.media
Are you over 18 and want to see adult content?
A complete backup of https://anekatempatwisata.com
Are you over 18 and want to see adult content?
A complete backup of https://hraadvisors.com
Are you over 18 and want to see adult content?
A complete backup of https://iocc.org
Are you over 18 and want to see adult content?
A complete backup of https://atkor.net
Are you over 18 and want to see adult content?
A complete backup of https://eurob.org
Are you over 18 and want to see adult content?
A complete backup of https://fotoilkem.com
Are you over 18 and want to see adult content?
A complete backup of https://usebraintrust.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of 7forallmankind.eu
Are you over 18 and want to see adult content?
A complete backup of morningstartv.com
Are you over 18 and want to see adult content?
A complete backup of vouchervandaag.nl
Are you over 18 and want to see adult content?
A complete backup of brakeconnect.com
Are you over 18 and want to see adult content?
A complete backup of kfc-uerdingen.de
Are you over 18 and want to see adult content?
A complete backup of bournemouth.gov.uk
Are you over 18 and want to see adult content?
A complete backup of kltcredit.com.ua
Are you over 18 and want to see adult content?
Text
AMICUS THERAPEUTICS
Amicus Therapeutics) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases. POMPE DISEASE PROGRAM Pompe disease is an inherited Lysosomal Storage Disorder (LSD) caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). Reduced or absent levels of GAA lead to the accumulation of the substrate glycogen in the lysosomes of muscles and other tissues. FABRY DISEASE PROGRAM Fabry disease is a rare, progressive genetic disorder characterized by a defective gene (GLA) that causes an enzyme deficiency. This enzyme is responsible for breaking down disease substrate that, when deficient in patients with Fabry disease, builds up in the kidneys,one of
BATTEN DISEASE INFORMATION In 2018, Amicus Therapeutics acquired a gene therapy portfolio of clinical and preclinical stage adeno associated virus (AAV) programs in lysosomal disorders through a license agreement with The Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital (NCH), including several forms of Batten disease.INVESTOR RELATIONS
A passionate team with a purpose. Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. JOHN F. CROWLEY, CHAIRMAN OF THE BOARD, CHIEF EXECUTIVE John F. Crowley is our Chairman and CEO. John’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. AMICUS THERAPEUTICS BOARD OF DIRECTORS A Passionate Team with a Purpose. We are driven toward invention and healing. Committed to delivering meaningful benefits to the rare and orphan disease community, our dedicated leadership team is the driving force behind our developments. CO-ADMINISTRATION OF THE PHARMACOLOGICAL CHAPERONE AT2221 Introduction. Co-Administration of the Pharmacological Chaperone AT2221 with A Proprietary Recombinant Human Acid . α-GlucosidaseLeads to Greater Plasma Exposure and SubstrateSEC FILINGS
The site you are about to enter is intended for US healthcare professionals. Please confirm you are a US healthcare professional. PHASE 3 STUDY (FACETS) OF MIGALASTAT HCL FOR FABRY DISEASE Clinical Trial HEK . GLP HEK : Number of Migalastat Concentrations Tested. 1 (0 and 10 μM migalastat) 11 (0 and 11-point migalastatconcentration-
AMICUS THERAPEUTICS
Amicus Therapeutics) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases. POMPE DISEASE PROGRAM Pompe disease is an inherited Lysosomal Storage Disorder (LSD) caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). Reduced or absent levels of GAA lead to the accumulation of the substrate glycogen in the lysosomes of muscles and other tissues. FABRY DISEASE PROGRAM Fabry disease is a rare, progressive genetic disorder characterized by a defective gene (GLA) that causes an enzyme deficiency. This enzyme is responsible for breaking down disease substrate that, when deficient in patients with Fabry disease, builds up in the kidneys,one of
BATTEN DISEASE INFORMATION In 2018, Amicus Therapeutics acquired a gene therapy portfolio of clinical and preclinical stage adeno associated virus (AAV) programs in lysosomal disorders through a license agreement with The Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital (NCH), including several forms of Batten disease.INVESTOR RELATIONS
A passionate team with a purpose. Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. JOHN F. CROWLEY, CHAIRMAN OF THE BOARD, CHIEF EXECUTIVE John F. Crowley is our Chairman and CEO. John’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. AMICUS THERAPEUTICS BOARD OF DIRECTORS A Passionate Team with a Purpose. We are driven toward invention and healing. Committed to delivering meaningful benefits to the rare and orphan disease community, our dedicated leadership team is the driving force behind our developments. CO-ADMINISTRATION OF THE PHARMACOLOGICAL CHAPERONE AT2221 Introduction. Co-Administration of the Pharmacological Chaperone AT2221 with A Proprietary Recombinant Human Acid . α-GlucosidaseLeads to Greater Plasma Exposure and SubstrateSEC FILINGS
The site you are about to enter is intended for US healthcare professionals. Please confirm you are a US healthcare professional. PHASE 3 STUDY (FACETS) OF MIGALASTAT HCL FOR FABRY DISEASE Clinical Trial HEK . GLP HEK : Number of Migalastat Concentrations Tested. 1 (0 and 10 μM migalastat) 11 (0 and 11-point migalastatconcentration-
ABOUT AMICUS THERAPEUTICS Amicus Therapeutics (Nasdaq:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for LEARN ABOUT GALAFOLD® Amicus Assist is a service that will provide product assistance and support to patients to help gain access to Amicus Therapeutics’ medications. For more information please call +1-833-AMICUS-A (+1-833-264-2872) or visit amicusassist.com. BATTEN DISEASE INFORMATION In 2018, Amicus Therapeutics acquired a gene therapy portfolio of clinical and preclinical stage adeno associated virus (AAV) programs in lysosomal disorders through a license agreement with The Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital (NCH), including several forms of Batten disease. CAREERS OPPORTUNITIES Amicus is an Equal Opportunity Employer and will judge all applicants based on their qualifications for the job, without regard to race, color, sex, religion, national origin, age, disability, sexual orientation, gender identity, protected veteran, disability status or any other characteristics protected by applicable federal, state orlocal law.
AMICUS THERAPEUTICS
Corporate Headquarters, Global Research & Gene Therapy Center of Excellence. Amicus Therapeutics, Inc. 3675 Market Street Philadelphia, PA 19104. Phone: 215-921-7600 Fax: 215-921-7900 info@amicusrx.com HIGHLIGHTS OF PRESCRIBING INFORMATION THE RECOMMENDED 5 adverse outcomes. In the U.S. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.SEC FILINGS
The site you are about to enter is intended for US healthcare professionals. Please confirm you are a US healthcare professional. DAPHNE QUIMI, CHIEF FINANCIAL OFFICER Daphne Quimi joined Amicus in September 2007 and currently serves as Chief Financial Officer. She brings experience in public accounting and financial reporting. ANNUAL REPORTS AND PROXIES The site you are about to enter is intended for US healthcare professionals. Please confirm you are a US healthcare professional. AMICUS THERAPEUTICS ACQUIRES GENE THERAPY PORTFOLIO OF TEN License with Nationwide Children’s Hospital (NCH) through the Acquisition of Celenex (NCH Spinout)Establishes Amicus as Leading Gene Therapy Company in Neurologic Lysosomal Storage Disorders (LSD) with Potential to Transform the Lives of 10,000+ Children with Fatal Genetic Diseases Includes Clinical Stage Programs in CLN6 and CLN3 Batten Disease, a Preclinical Program in CLN8AMICUS THERAPEUTICS
Amicus Therapeutics) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases.INVESTOR RELATIONS
A passionate team with a purpose. Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. POMPE DISEASE PROGRAM Pompe disease is an inherited Lysosomal Storage Disorder (LSD) caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). Reduced or absent levels of GAA lead to the accumulation of the substrate glycogen in the lysosomes of muscles and other tissues. BATTEN DISEASE INFORMATION In 2018, Amicus Therapeutics acquired a gene therapy portfolio of ten clinical and preclinical stage adeno associated virus (AAV) programs in lysosomal disorders through a license agreement with The Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital (NCH), including several forms of Batten disease. AMICUS THERAPEUTICS BOARD OF DIRECTORS A Passionate Team with a Purpose. We are driven toward invention and healing. Committed to delivering meaningful benefits to the rare and orphan disease community, our dedicated leadership team is the driving force behind our developments. JOHN F. CROWLEY, CHAIRMAN OF THE BOARD, CHIEF EXECUTIVE John F. Crowley is our Chairman and CEO. John’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. FABRY DISEASE PROGRAM Fabry disease is a rare, progressive genetic disorder characterized by a defective gene (GLA) that causes an enzyme deficiency. This enzyme is responsible for breaking down disease substrate that, when deficient in patients with Fabry disease, builds up in the kidneys,one of
ANNUAL REPORTS AND PROXIES The site you are about to enter is intended for US healthcare professionals. Please confirm you are a US healthcare professional. AMICUS THERAPEUTICS APPOINTS SÉBASTIEN MARTEL AS SENIOR The site you are about to enter is intended for US healthcare professionals. Please confirm you are a US healthcare professional. PHASE 3 STUDY (FACETS) OF MIGALASTAT HCL FOR FABRY DISEASE Clinical Trial HEK . GLP HEK : Number of Migalastat Concentrations Tested. 1 (0 and 10 μM migalastat) 11 (0 and 11-point migalastatconcentration-
AMICUS THERAPEUTICS
Amicus Therapeutics) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases.INVESTOR RELATIONS
A passionate team with a purpose. Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. POMPE DISEASE PROGRAM Pompe disease is an inherited Lysosomal Storage Disorder (LSD) caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). Reduced or absent levels of GAA lead to the accumulation of the substrate glycogen in the lysosomes of muscles and other tissues. BATTEN DISEASE INFORMATION In 2018, Amicus Therapeutics acquired a gene therapy portfolio of ten clinical and preclinical stage adeno associated virus (AAV) programs in lysosomal disorders through a license agreement with The Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital (NCH), including several forms of Batten disease. AMICUS THERAPEUTICS BOARD OF DIRECTORS A Passionate Team with a Purpose. We are driven toward invention and healing. Committed to delivering meaningful benefits to the rare and orphan disease community, our dedicated leadership team is the driving force behind our developments. JOHN F. CROWLEY, CHAIRMAN OF THE BOARD, CHIEF EXECUTIVE John F. Crowley is our Chairman and CEO. John’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. FABRY DISEASE PROGRAM Fabry disease is a rare, progressive genetic disorder characterized by a defective gene (GLA) that causes an enzyme deficiency. This enzyme is responsible for breaking down disease substrate that, when deficient in patients with Fabry disease, builds up in the kidneys,one of
ANNUAL REPORTS AND PROXIES The site you are about to enter is intended for US healthcare professionals. Please confirm you are a US healthcare professional. AMICUS THERAPEUTICS APPOINTS SÉBASTIEN MARTEL AS SENIOR The site you are about to enter is intended for US healthcare professionals. Please confirm you are a US healthcare professional. PHASE 3 STUDY (FACETS) OF MIGALASTAT HCL FOR FABRY DISEASE Clinical Trial HEK . GLP HEK : Number of Migalastat Concentrations Tested. 1 (0 and 10 μM migalastat) 11 (0 and 11-point migalastatconcentration-
ABOUT AMICUS THERAPEUTICS Amicus Therapeutics (Nasdaq:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for LEARN ABOUT GALAFOLD® Amicus Assist is a service that will provide product assistance and support to patients to help gain access to Amicus Therapeutics’ medications. For more information please call +1-833-AMICUS-A (+1-833-264-2872) or visit amicusassist.com.INVESTOR RELATIONS
A passionate team with a purpose. Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases.AMICUS THERAPEUTICS
Corporate Headquarters, Global Research & Gene Therapy Center of Excellence. Amicus Therapeutics, Inc. 3675 Market Street Philadelphia, PA 19104. Phone: 215-921-7600 Fax: 215-921-7900 info@amicusrx.com GLOBAL MEDICAL AFFAIRS PROGRAM Independent Medical Education Program Grants Accredited Medical Education Program Grants (U.S.) Amicus Therapeutics supports programs and activities that foster excellence in patient care and provide valuable scientific, medical, and educational information to theCRAIG A. WHEELER
Craig A. Wheeler has served as a member of our Board since June 2016. Mr. Wheeler previously served as President and Chief Executive Officer of Momenta Pharmaceuticals, Inc., where he also served on the Board ofDirectors.
DAPHNE QUIMI, CHIEF FINANCIAL OFFICER Daphne Quimi joined Amicus in September 2007 and currently serves as Chief Financial Officer. She brings experience in public accounting and financial reporting. HIGHLIGHTS OF PRESCRIBING INFORMATION THE RECOMMENDED 5 adverse outcomes. In the U.S. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. EVENTS & PRESENTATIONS The site you are about to enter is intended for US healthcare professionals. Please confirm you are a US healthcare professional. AMICUS THERAPEUTICS ACQUIRES GENE THERAPY PORTFOLIO OF TEN License with Nationwide Children’s Hospital (NCH) through the Acquisition of Celenex (NCH Spinout)Establishes Amicus as Leading Gene Therapy Company in Neurologic Lysosomal Storage Disorders (LSD) with Potential to Transform the Lives of 10,000+ Children with Fatal Genetic Diseases Includes Clinical Stage Programs in CLN6 and CLN3 Batten Disease, a Preclinical Program in CLN8AMICUS THERAPEUTICS
Amicus Therapeutics) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases. AMICUS THERAPEUTICS PROGRAMS & PIPELINE Fabry Disease. Fabry disease is a rare, progressive genetic disorder characterized by a defective gene (GLA) that causes an enzyme deficiency.This enzyme is responsible for breaking down disease substrate that, when deficient in patients with Fabry disease, builds up in the kidneys, one of the organ systems impacted by Fabry disease. CAREERS OPPORTUNITIESINVESTOR RELATIONS
A passionate team with a purpose. Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for peopleliving
POMPE DISEASE PROGRAM Pompe disease is an inherited Lysosomal Storage Disorder (LSD) caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). Reduced or absent levels of GAA lead to the accumulation of the substrate glycogen in the lysosomes of muscles and other tissues. Progressive accumulation of glycogen is believed to lead to the morbidity and JOHN F. CROWLEY, CHAIRMAN OF THE BOARD, CHIEF EXECUTIVE John F. Crowley is our Chairman and CEO. John’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder,President and
AMICUS THERAPEUTICS BOARD OF DIRECTORS Committed to delivering meaningful benefits to the rare and orphan disease community, our dedicated leadership team is the driving force behind our developments. They are constantly inspired by others in the rare disease community, and continually aspire to reach new heights. Senior Management Team Board of Directors. FABRY DISEASE PROGRAM Fabry disease is a rare, progressive genetic disorder characterized by a defective gene (GLA) that causes an enzyme deficiency. This enzyme is responsible for breaking down disease substrate that, when deficient in patients with Fabry disease, builds up in the kidneys,one of
BATTEN DISEASE INFORMATION Batten disease is the common name for a broad class of rare, fatal, inherited disorders of the nervous system also known as neuronal ceroid lipofuscinoses, or NCLs. In these diseases, a defect in a specific gene triggers a cascade of problems that interferes with a cell’s ability to recycle certain molecules. BRADLY L. CAMPBELL, PRESIDENT AND CHIEF OPERATING OFFICER Bradley L. Campbell is the President and Chief Operating Officer of Amicus Therapeutics and is also a member of the Board of Directors. He brings nearly 20 years of experience in the Orphan Drug industry. Mr. Campbell joined Amicus in 2006 and leads the global organization responsible for the commercialization of Galafold®.AMICUS THERAPEUTICS
Amicus Therapeutics) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases. AMICUS THERAPEUTICS PROGRAMS & PIPELINE Fabry Disease. Fabry disease is a rare, progressive genetic disorder characterized by a defective gene (GLA) that causes an enzyme deficiency.This enzyme is responsible for breaking down disease substrate that, when deficient in patients with Fabry disease, builds up in the kidneys, one of the organ systems impacted by Fabry disease. CAREERS OPPORTUNITIESINVESTOR RELATIONS
A passionate team with a purpose. Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for peopleliving
POMPE DISEASE PROGRAM Pompe disease is an inherited Lysosomal Storage Disorder (LSD) caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). Reduced or absent levels of GAA lead to the accumulation of the substrate glycogen in the lysosomes of muscles and other tissues. Progressive accumulation of glycogen is believed to lead to the morbidity and JOHN F. CROWLEY, CHAIRMAN OF THE BOARD, CHIEF EXECUTIVE John F. Crowley is our Chairman and CEO. John’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder,President and
AMICUS THERAPEUTICS BOARD OF DIRECTORS Committed to delivering meaningful benefits to the rare and orphan disease community, our dedicated leadership team is the driving force behind our developments. They are constantly inspired by others in the rare disease community, and continually aspire to reach new heights. Senior Management Team Board of Directors. FABRY DISEASE PROGRAM Fabry disease is a rare, progressive genetic disorder characterized by a defective gene (GLA) that causes an enzyme deficiency. This enzyme is responsible for breaking down disease substrate that, when deficient in patients with Fabry disease, builds up in the kidneys,one of
BATTEN DISEASE INFORMATION Batten disease is the common name for a broad class of rare, fatal, inherited disorders of the nervous system also known as neuronal ceroid lipofuscinoses, or NCLs. In these diseases, a defect in a specific gene triggers a cascade of problems that interferes with a cell’s ability to recycle certain molecules. BRADLY L. CAMPBELL, PRESIDENT AND CHIEF OPERATING OFFICER Bradley L. Campbell is the President and Chief Operating Officer of Amicus Therapeutics and is also a member of the Board of Directors. He brings nearly 20 years of experience in the Orphan Drug industry. Mr. Campbell joined Amicus in 2006 and leads the global organization responsible for the commercialization of Galafold®. ABOUT AMICUS THERAPEUTICS We are a global biotechnology company at the forefront of advancing therapies for a range of rare and devastating diseases and our excellent team has a very big and a very bold vision. Each program that we invest in has to have three key characteristics. It has to be in the rare diseases for a devastating disorder, the technology has tohave
AMICUS THERAPEUTICS PROGRAMS & PIPELINE Fabry Disease. Fabry disease is a rare, progressive genetic disorder characterized by a defective gene (GLA) that causes an enzyme deficiency.This enzyme is responsible for breaking down disease substrate that, when deficient in patients with Fabry disease, builds up in the kidneys, one of the organ systems impacted by Fabry disease. LEARN ABOUT GALAFOLD® Amicus Assist is a service that will provide product assistance and support to patients to help gain access to Amicus Therapeutics’ medications. For more information please call +1-833-AMICUS-A (+1-833-264-2872) or visit amicusassist.com.AMICUS THERAPEUTICS
Corporate Headquarters, Global Research & Gene Therapy Center of Excellence. Amicus Therapeutics, Inc. 3675 Market Street Philadelphia, PA 19104. Phone: 215-921-7600 Fax: 215-921-7900 info@amicusrx.comSEC FILINGS
May 10, 2021. Quarterly report which provides a continuing view of a company's financial position. 10-Q. Quarterly Filings. View HTML. 0001178879-21-000006.pdf. 0001178879-21-000006.xls. OUR BELIEF STATEMENT In 2005, the employees of Amicus crafted a belief statement that would encompass our core values and remind us of the reason we do what we do every day. These highly valued statements outline the fundamental beliefs that are crucial to understanding the passion and commitmentbehind Amicus.
BRADLY L. CAMPBELL, PRESIDENT AND CHIEF OPERATING OFFICER Bradley L. Campbell is the President and Chief Operating Officer of Amicus Therapeutics and is also a member of the Board of Directors. He brings nearly 20 years of experience in the Orphan Drug industry. Mr. Campbell joined Amicus in 2006 and leads the global organization responsible for the commercialization of Galafold®. AMICUS’ AT-GAA SHOWS CLINICALLY MEANINGFUL & SIGNIFICANT Rolling BLA submission for AT-GAA planned for completion in Q2 and other global regulatory submissions for approval expected throughout 2021. Patients switching to AT-GAA from the approved standard of care ERT (alglucosidase alfa) walked on average 17 meters farther (p=0.046) HIGHLIGHTS OF PRESCRIBING INFORMATION THE … 5 adverse outcomes. In the U.S. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. ANNUAL REPORTS AND PROXIES The site you are about to enter is intended for US healthcare professionals. Please confirm you are a US healthcare professional.AMICUS THERAPEUTICS
Amicus Therapeutics) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases.INVESTOR RELATIONS
A passionate team with a purpose. Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for peopleliving
POMPE DISEASE PROGRAM Pompe disease is an inherited Lysosomal Storage Disorder (LSD) caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). Reduced or absent levels of GAA lead to the accumulation of the substrate glycogen in the lysosomes of muscles and other tissues. Progressive accumulation of glycogen is believed to lead to the morbidity and AMICUS THERAPEUTICS BOARD OF DIRECTORS Committed to delivering meaningful benefits to the rare and orphan disease community, our dedicated leadership team is the driving force behind our developments. They are constantly inspired by others in the rare disease community, and continually aspire to reach new heights. Senior Management Team Board of Directors. BATTEN DISEASE INFORMATION Batten disease is the common name for a broad class of rare, fatal, inherited disorders of the nervous system also known as neuronal ceroid lipofuscinoses, or NCLs. In these diseases, a defect in a specific gene triggers a cascade of problems that interferes with a cell’s ability to recycle certain molecules. FABRY DISEASE PROGRAM Fabry disease is a rare, progressive genetic disorder characterized by a defective gene (GLA) that causes an enzyme deficiency. This enzyme is responsible for breaking down disease substrate that, when deficient in patients with Fabry disease, builds up in the kidneys,one of
JOHN F. CROWLEY, CHAIRMAN OF THE BOARD, CHIEF EXECUTIVE John F. Crowley is our Chairman and CEO. John’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder,President and
CRAIG A. WHEELER
Craig A. Wheeler has served as a member of our Board since June 2016. Mr. Wheeler previously served as President and Chief Executive Officer of Momenta Pharmaceuticals, Inc., where he also served on the Board of Directors. He led Momenta through the launch of its first complex drug products, including the first generic versions of LOVENOX® and AMICUS THERAPEUTICS APPOINTS SÉBASTIEN MARTEL AS SENIOR The site you are about to enter is intended for US healthcare professionals. Please confirm you are a US healthcare professional. PHASE 3 STUDY (FACETS) OF MIGALASTAT HCL FOR FABRY DISEASE Clinical Trial HEK . GLP HEK : Number of Migalastat Concentrations Tested. 1 (0 and 10 μM migalastat) 11 (0 and 11-point migalastatconcentration-
AMICUS THERAPEUTICS
Amicus Therapeutics) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases.INVESTOR RELATIONS
A passionate team with a purpose. Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for peopleliving
POMPE DISEASE PROGRAM Pompe disease is an inherited Lysosomal Storage Disorder (LSD) caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). Reduced or absent levels of GAA lead to the accumulation of the substrate glycogen in the lysosomes of muscles and other tissues. Progressive accumulation of glycogen is believed to lead to the morbidity and AMICUS THERAPEUTICS BOARD OF DIRECTORS Committed to delivering meaningful benefits to the rare and orphan disease community, our dedicated leadership team is the driving force behind our developments. They are constantly inspired by others in the rare disease community, and continually aspire to reach new heights. Senior Management Team Board of Directors. BATTEN DISEASE INFORMATION Batten disease is the common name for a broad class of rare, fatal, inherited disorders of the nervous system also known as neuronal ceroid lipofuscinoses, or NCLs. In these diseases, a defect in a specific gene triggers a cascade of problems that interferes with a cell’s ability to recycle certain molecules. FABRY DISEASE PROGRAM Fabry disease is a rare, progressive genetic disorder characterized by a defective gene (GLA) that causes an enzyme deficiency. This enzyme is responsible for breaking down disease substrate that, when deficient in patients with Fabry disease, builds up in the kidneys,one of
JOHN F. CROWLEY, CHAIRMAN OF THE BOARD, CHIEF EXECUTIVE John F. Crowley is our Chairman and CEO. John’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder,President and
CRAIG A. WHEELER
Craig A. Wheeler has served as a member of our Board since June 2016. Mr. Wheeler previously served as President and Chief Executive Officer of Momenta Pharmaceuticals, Inc., where he also served on the Board of Directors. He led Momenta through the launch of its first complex drug products, including the first generic versions of LOVENOX® and AMICUS THERAPEUTICS APPOINTS SÉBASTIEN MARTEL AS SENIOR The site you are about to enter is intended for US healthcare professionals. Please confirm you are a US healthcare professional. PHASE 3 STUDY (FACETS) OF MIGALASTAT HCL FOR FABRY DISEASE Clinical Trial HEK . GLP HEK : Number of Migalastat Concentrations Tested. 1 (0 and 10 μM migalastat) 11 (0 and 11-point migalastatconcentration-
ABOUT AMICUS THERAPEUTICS We are a global biotechnology company at the forefront of advancing therapies for a range of rare and devastating diseases and our excellent team has a very big and a very bold vision. Each program that we invest in has to have three key characteristics. It has to be in the rare diseases for a devastating disorder, the technology has tohave
AMICUS THERAPEUTICS PROGRAMS & PIPELINE Fabry Disease. Fabry disease is a rare, progressive genetic disorder characterized by a defective gene (GLA) that causes an enzyme deficiency.This enzyme is responsible for breaking down disease substrate that, when deficient in patients with Fabry disease, builds up in the kidneys, one of the organ systems impacted by Fabry disease.AMICUS THERAPEUTICS
Corporate Headquarters, Global Research & Gene Therapy Center of Excellence. Amicus Therapeutics, Inc. 3675 Market Street Philadelphia, PA 19104. Phone: 215-921-7600 Fax: 215-921-7900 info@amicusrx.com GLOBAL MEDICAL AFFAIRS PROGRAM Amicus Therapeutics requires that a fully-executed Letter of Agreement (LOA), in the form provided by Amicus Therapeutics, be signed by the requesting Continuing Education Provider and Amicus Therapeutics Global Medical Affairs Independent Medical Education prior to the commencement of the Continuing Education program.CRAIG A. WHEELER
Craig A. Wheeler has served as a member of our Board since June 2016. Mr. Wheeler previously served as President and Chief Executive Officer of Momenta Pharmaceuticals, Inc., where he also served on the Board of Directors. He led Momenta through the launch of its first complex drug products, including the first generic versions of LOVENOX® and CORPORATE GOVERNANCE Corporate Governance. The Board of Directors of Amicus Therapeutics, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and tooversee
DAPHNE QUIMI, CHIEF FINANCIAL OFFICER Daphne Quimi joined Amicus in September 2007 and currently serves as Chief Financial Officer. She brings experience in public accounting and financial reporting. Prior to Amicus, Ms. Quimi served as Director of Consolidations and External Reporting at Bristol-Myers Squibb. She also held roles of increasing responsibility in the finance HIGHLIGHTS OF PRESCRIBING INFORMATION THE … 5 adverse outcomes. In the U.S. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. AMICUS THERAPEUTICS ACQUIRES GENE THERAPY PORTFOLIO OF TEN License with Nationwide Children’s Hospital (NCH) through the Acquisition of Celenex (NCH Spinout)Establishes Amicus as Leading Gene Therapy Company in Neurologic Lysosomal Storage Disorders (LSD) with Potential to Transform the Lives of 10,000+ Children with Fatal Genetic Diseases Includes Clinical Stage Programs in CLN6 and CLN3 Batten Disease, a Preclinical Program in CLN8 ESSENTIAL GOVERNANCE DOCUMENTS & COMMITTEES CHARTERS The site you are about to enter is intended for US healthcare professionals. Please confirm you are a US healthcare professional.AMICUS THERAPEUTICS
Amicus Therapeutics) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases.INVESTOR RELATIONS
A passionate team with a purpose. Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for peopleliving
POMPE DISEASE PROGRAM Pompe disease is an inherited Lysosomal Storage Disorder (LSD) caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). Reduced or absent levels of GAA lead to the accumulation of the substrate glycogen in the lysosomes of muscles and other tissues. Progressive accumulation of glycogen is believed to lead to the morbidity and AMICUS THERAPEUTICS BOARD OF DIRECTORS Committed to delivering meaningful benefits to the rare and orphan disease community, our dedicated leadership team is the driving force behind our developments. They are constantly inspired by others in the rare disease community, and continually aspire to reach new heights. Senior Management Team Board of Directors. BATTEN DISEASE INFORMATION Batten disease is the common name for a broad class of rare, fatal, inherited disorders of the nervous system also known as neuronal ceroid lipofuscinoses, or NCLs. In these diseases, a defect in a specific gene triggers a cascade of problems that interferes with a cell’s ability to recycle certain molecules. FABRY DISEASE PROGRAM Fabry disease is a rare, progressive genetic disorder characterized by a defective gene (GLA) that causes an enzyme deficiency. This enzyme is responsible for breaking down disease substrate that, when deficient in patients with Fabry disease, builds up in the kidneys,one of
JOHN F. CROWLEY, CHAIRMAN OF THE BOARD, CHIEF EXECUTIVE John F. Crowley is our Chairman and CEO. John’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder,President and
CRAIG A. WHEELER
Craig A. Wheeler has served as a member of our Board since June 2016. Mr. Wheeler previously served as President and Chief Executive Officer of Momenta Pharmaceuticals, Inc., where he also served on the Board of Directors. He led Momenta through the launch of its first complex drug products, including the first generic versions of LOVENOX® and AMICUS THERAPEUTICS APPOINTS SÉBASTIEN MARTEL AS SENIOR The site you are about to enter is intended for US healthcare professionals. Please confirm you are a US healthcare professional. PHASE 3 STUDY (FACETS) OF MIGALASTAT HCL FOR FABRY DISEASE Clinical Trial HEK . GLP HEK : Number of Migalastat Concentrations Tested. 1 (0 and 10 μM migalastat) 11 (0 and 11-point migalastatconcentration-
AMICUS THERAPEUTICS
Amicus Therapeutics) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases.INVESTOR RELATIONS
A passionate team with a purpose. Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for peopleliving
POMPE DISEASE PROGRAM Pompe disease is an inherited Lysosomal Storage Disorder (LSD) caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). Reduced or absent levels of GAA lead to the accumulation of the substrate glycogen in the lysosomes of muscles and other tissues. Progressive accumulation of glycogen is believed to lead to the morbidity and AMICUS THERAPEUTICS BOARD OF DIRECTORS Committed to delivering meaningful benefits to the rare and orphan disease community, our dedicated leadership team is the driving force behind our developments. They are constantly inspired by others in the rare disease community, and continually aspire to reach new heights. Senior Management Team Board of Directors. BATTEN DISEASE INFORMATION Batten disease is the common name for a broad class of rare, fatal, inherited disorders of the nervous system also known as neuronal ceroid lipofuscinoses, or NCLs. In these diseases, a defect in a specific gene triggers a cascade of problems that interferes with a cell’s ability to recycle certain molecules. FABRY DISEASE PROGRAM Fabry disease is a rare, progressive genetic disorder characterized by a defective gene (GLA) that causes an enzyme deficiency. This enzyme is responsible for breaking down disease substrate that, when deficient in patients with Fabry disease, builds up in the kidneys,one of
JOHN F. CROWLEY, CHAIRMAN OF THE BOARD, CHIEF EXECUTIVE John F. Crowley is our Chairman and CEO. John’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder,President and
CRAIG A. WHEELER
Craig A. Wheeler has served as a member of our Board since June 2016. Mr. Wheeler previously served as President and Chief Executive Officer of Momenta Pharmaceuticals, Inc., where he also served on the Board of Directors. He led Momenta through the launch of its first complex drug products, including the first generic versions of LOVENOX® and AMICUS THERAPEUTICS APPOINTS SÉBASTIEN MARTEL AS SENIOR The site you are about to enter is intended for US healthcare professionals. Please confirm you are a US healthcare professional. PHASE 3 STUDY (FACETS) OF MIGALASTAT HCL FOR FABRY DISEASE Clinical Trial HEK . GLP HEK : Number of Migalastat Concentrations Tested. 1 (0 and 10 μM migalastat) 11 (0 and 11-point migalastatconcentration-
ABOUT AMICUS THERAPEUTICS We are a global biotechnology company at the forefront of advancing therapies for a range of rare and devastating diseases and our excellent team has a very big and a very bold vision. Each program that we invest in has to have three key characteristics. It has to be in the rare diseases for a devastating disorder, the technology has tohave
AMICUS THERAPEUTICS PROGRAMS & PIPELINE Fabry Disease. Fabry disease is a rare, progressive genetic disorder characterized by a defective gene (GLA) that causes an enzyme deficiency.This enzyme is responsible for breaking down disease substrate that, when deficient in patients with Fabry disease, builds up in the kidneys, one of the organ systems impacted by Fabry disease.AMICUS THERAPEUTICS
Corporate Headquarters, Global Research & Gene Therapy Center of Excellence. Amicus Therapeutics, Inc. 3675 Market Street Philadelphia, PA 19104. Phone: 215-921-7600 Fax: 215-921-7900 info@amicusrx.com GLOBAL MEDICAL AFFAIRS PROGRAM Amicus Therapeutics requires that a fully-executed Letter of Agreement (LOA), in the form provided by Amicus Therapeutics, be signed by the requesting Continuing Education Provider and Amicus Therapeutics Global Medical Affairs Independent Medical Education prior to the commencement of the Continuing Education program.CRAIG A. WHEELER
Craig A. Wheeler has served as a member of our Board since June 2016. Mr. Wheeler previously served as President and Chief Executive Officer of Momenta Pharmaceuticals, Inc., where he also served on the Board of Directors. He led Momenta through the launch of its first complex drug products, including the first generic versions of LOVENOX® and CORPORATE GOVERNANCE Corporate Governance. The Board of Directors of Amicus Therapeutics, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and tooversee
DAPHNE QUIMI, CHIEF FINANCIAL OFFICER Daphne Quimi joined Amicus in September 2007 and currently serves as Chief Financial Officer. She brings experience in public accounting and financial reporting. Prior to Amicus, Ms. Quimi served as Director of Consolidations and External Reporting at Bristol-Myers Squibb. She also held roles of increasing responsibility in the finance HIGHLIGHTS OF PRESCRIBING INFORMATION THE … 5 adverse outcomes. In the U.S. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. ESSENTIAL GOVERNANCE DOCUMENTS & COMMITTEES CHARTERS The site you are about to enter is intended for US healthcare professionals. Please confirm you are a US healthcare professional. CO-ADMINISTRATION OF THE PHARMACOLOGICAL CHAPERONE AT2221 Introduction. Co-Administration of the Pharmacological Chaperone AT2221 with A Proprietary Recombinant Human Acid . α-GlucosidaseLeads to Greater Plasma Exposure and SubstrateAMICUS THERAPEUTICS
Amicus Therapeutics) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases. ABOUT AMICUS THERAPEUTICS We are a global biotechnology company at the forefront of advancing therapies for a range of rare and devastating diseases and our excellent team has a very big and a very bold vision. Each program that we invest in has to have three key characteristics. It has to be in the rare diseases for a devastating disorder, the technology has tohave
AMICUS THERAPEUTICS PROGRAMS & PIPELINE Fabry Disease. Fabry disease is a rare, progressive genetic disorder characterized by a defective gene (GLA) that causes an enzyme deficiency.This enzyme is responsible for breaking down disease substrate that, when deficient in patients with Fabry disease, builds up in the kidneys, one of the organ systems impacted by Fabry disease.INVESTOR RELATIONS
A passionate team with a purpose. Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for peopleliving
CAREERS OPPORTUNITIESAMICUS THERAPEUTICS
Corporate Headquarters, Global Research & Gene Therapy Center of Excellence. Amicus Therapeutics, Inc. 3675 Market Street Philadelphia, PA 19104. Phone: 215-921-7600 Fax: 215-921-7900 info@amicusrx.com POMPE DISEASE PROGRAM Pompe disease is an inherited Lysosomal Storage Disorder (LSD) caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). Reduced or absent levels of GAA lead to the accumulation of the substrate glycogen in the lysosomes of muscles and other tissues. Progressive accumulation of glycogen is believed to lead to the morbidity and FABRY DISEASE PROGRAM Fabry disease is a rare, progressive genetic disorder characterized by a defective gene (GLA) that causes an enzyme deficiency. This enzyme is responsible for breaking down disease substrate that, when deficient in patients with Fabry disease, builds up in the kidneys,one of
AMICUS THERAPEUTICS BOARD OF DIRECTORS Committed to delivering meaningful benefits to the rare and orphan disease community, our dedicated leadership team is the driving force behind our developments. They are constantly inspired by others in the rare disease community, and continually aspire to reach new heights. Senior Management Team Board of Directors. BATTEN DISEASE INFORMATION Batten disease is the common name for a broad class of rare, fatal, inherited disorders of the nervous system also known as neuronal ceroid lipofuscinoses, or NCLs. In these diseases, a defect in a specific gene triggers a cascade of problems that interferes with a cell’s ability to recycle certain molecules.AMICUS THERAPEUTICS
Amicus Therapeutics) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases. ABOUT AMICUS THERAPEUTICS We are a global biotechnology company at the forefront of advancing therapies for a range of rare and devastating diseases and our excellent team has a very big and a very bold vision. Each program that we invest in has to have three key characteristics. It has to be in the rare diseases for a devastating disorder, the technology has tohave
AMICUS THERAPEUTICS PROGRAMS & PIPELINE Fabry Disease. Fabry disease is a rare, progressive genetic disorder characterized by a defective gene (GLA) that causes an enzyme deficiency.This enzyme is responsible for breaking down disease substrate that, when deficient in patients with Fabry disease, builds up in the kidneys, one of the organ systems impacted by Fabry disease.INVESTOR RELATIONS
A passionate team with a purpose. Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for peopleliving
CAREERS OPPORTUNITIESAMICUS THERAPEUTICS
Corporate Headquarters, Global Research & Gene Therapy Center of Excellence. Amicus Therapeutics, Inc. 3675 Market Street Philadelphia, PA 19104. Phone: 215-921-7600 Fax: 215-921-7900 info@amicusrx.com POMPE DISEASE PROGRAM Pompe disease is an inherited Lysosomal Storage Disorder (LSD) caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). Reduced or absent levels of GAA lead to the accumulation of the substrate glycogen in the lysosomes of muscles and other tissues. Progressive accumulation of glycogen is believed to lead to the morbidity and FABRY DISEASE PROGRAM Fabry disease is a rare, progressive genetic disorder characterized by a defective gene (GLA) that causes an enzyme deficiency. This enzyme is responsible for breaking down disease substrate that, when deficient in patients with Fabry disease, builds up in the kidneys,one of
AMICUS THERAPEUTICS BOARD OF DIRECTORS Committed to delivering meaningful benefits to the rare and orphan disease community, our dedicated leadership team is the driving force behind our developments. They are constantly inspired by others in the rare disease community, and continually aspire to reach new heights. Senior Management Team Board of Directors. BATTEN DISEASE INFORMATION Batten disease is the common name for a broad class of rare, fatal, inherited disorders of the nervous system also known as neuronal ceroid lipofuscinoses, or NCLs. In these diseases, a defect in a specific gene triggers a cascade of problems that interferes with a cell’s ability to recycle certain molecules. ABOUT AMICUS THERAPEUTICS Amicus Therapeutics (Nasdaq:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for LEARN ABOUT GALAFOLD® Amicus Assist is a service that will provide product assistance and support to patients to help gain access to Amicus Therapeutics’ medications. For more information please call +1-833-AMICUS-A (+1-833-264-2872) or visit amicusassist.com.AMICUS THERAPEUTICS
Corporate Headquarters, Global Research & Gene Therapy Center of Excellence. Amicus Therapeutics, Inc. 3675 Market Street Philadelphia, PA 19104. Phone: 215-921-7600 Fax: 215-921-7900 info@amicusrx.com AMICUS THERAPEUTICS DEVELOPMENT PIPELINE Development Pipeline. At Amicus we are business led and science driven to deliver meaningful benefits to patients. We believe that our advanced product pipeline and platform technologies uniquely position us at the forefront of developing therapies to potentially address significant unmet needs for GLOBAL MEDICAL AFFAIRS PROGRAM Amicus Therapeutics requires that a fully-executed Letter of Agreement (LOA), in the form provided by Amicus Therapeutics, be signed by the requesting Continuing Education Provider and Amicus Therapeutics Global Medical Affairs Independent Medical Education prior to the commencement of the Continuing Education program.2021 - AMICUSRX.COM
2021 ENVIRONMENTAL SOCIAL GOVERNANCE REPORT | 33 Amicus, the Latin word for friend, signifies our collaborative approach to developingmedicines by
OUR BELIEF STATEMENT In 2005, the employees of Amicus crafted a belief statement that would encompass our core values and remind us of the reason we do what we do every day. These highly valued statements outline the fundamental beliefs that are crucial to understanding the passion and commitmentbehind Amicus.
JOHN F. CROWLEY, CHAIRMAN OF THE BOARD, CHIEF EXECUTIVE John F. Crowley is our Chairman and CEO. John’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder,President and
CRAIG A. WHEELER
Craig A. Wheeler has served as a member of our Board since June 2016. Mr. Wheeler previously served as President and Chief Executive Officer of Momenta Pharmaceuticals, Inc., where he also served on the Board of Directors. He led Momenta through the launch of its first complex drug products, including the first generic versions of LOVENOX® andWWW.AMICUSRX.COM
www.amicusrx.com
* __
* __
* __
* Contact Us
* Global
* International
* Canada
* France
* Germany
* Italy
* Japan
* Netherlands
* Spain
×
* About Amicus
* About Amicus
* Chairman’s Welcome* Leadership
* Belief Statement
* Contact Us
* Message from BIO
* Patient Advocacy
* Patient Advocacy
* Disease Information* Rare Stories
* Patient Advisory Boards* Corporate Giving
* Resources
* Expanded Access
* Programs & Pipeline * Programs & Pipeline* Our Pipeline
* Fabry Disease
* Pompe Disease
* Batten Disease
* Additional Preclinical Programs* Clinical Trials
* Platform Technologies* Journal Articles
* Publications & Posters* Product
* Product
* Galafold®
* Amicus Assist™
* Responsibility
* Responsibility
* Ethics & Compliance * Global Medical Affairs* Corporate Giving
* Healing Beyond Disease* Investors & Media
* Investors & Media
* Investor Relations * Senior Management Team * Board of Directors * Corporate Governance* Press Releases
* Events & Presentations * Annual Reports & Proxies* SEC Filings
* Stock Performance
* Investor FAQs
* Contact Us
* Sign Up for Email Alerts* Featured Coverage
* Electronic Press Kit* Careers
* Careers
* Overview
* Search
OUR PASSION FOR MAKING A DIFFERENCE UNITES US. Amicus Therapeutics is a global, patient-dedicated biotech focused on discovering, developing, and delivering high-quality medicines for people living with rare metabolicdiseases.
MORE ›
KATELYNNAGE 11
LIVING WITH CDKL5 DEFICIENCY DISORDERRead her story ›
ABOUT AMICUS
We are a biotechnology company at the forefront of advanced therapies to treat a range of devasting rare diseases. EXTRAORDINARY PATIENT FOCUS At Amicus, patient-centricity is in our DNA. See how our commitment to patients goes further than just our medicines and expands out to the rare disease community at large. NEWS & ANNOUNCEMENTSMARCH 19, 2020
TO OUR PATIENT COMMUNITY PARTNERS: First and foremost, your safety and welfare and that of your families always has been and continues to be our number one priority. This is especially true in view of the global COVID-19 outbreak. Amicus remains committed to open and frequent communications to address any questions. We are in this fight together. We will maintain consistent monitoring of this unprecedented situation, provide updates of any changes and remain available to you. Given current information, we have a high degree of confidence that all Amicus-sponsored clinical studies across all programs are continuing as planned, and that supply of Galafold® will continueuninterrupted.
RESOURCES:
CLINICAL STUDY PARTICIPANTS and their family members can bring specific questions to their respective study site staff, as well as to Amicus Patient & Professional Advocacy at patientadvocacy@amicusrx.com or 1-866-9-AMICUS (926-4287) toll-free in the US and Canada or+1.609-662.2000.
FOR THOSE PRESCRIBED GALAFOLD® in the US, you can call Amicus assist toll free at 1-833-AMICUS-A (1-833-264-2872), or reach out to your healthcare provider. ❯ RESOURCES AND MORE INFORMATION BY PROGRAMPROGRAMS & PIPELINE
We are leveraging our innovative technology platforms to develop treatments for human genetic diseases.More ❯
RARE STORIES
Be inspired by people living with rare disease across the globe.More ❯
CAREER @ AMICUS
Join a team committed to changing the lives of patients with rare metabolic diseases. Now hiring in multiple locations.More ❯
* About Amicus
* Chairman’s Welcome* Leadership
* Belief Statement
* Contact Us
* Message from BIO
* Patient Advocacy
* Disease Information* Rare Stories
* Patient Advisory Boards* Corporate Giving
* Resources
* Expanded Access
* Programs & Pipeline* Pipeline
* Our Programs
* Clinical Trials
* Platform Technologies * Publications & Posters* Journal Articles
* Product
* Overview
* Amicus Assist™
* Responsibility
* Ethics & Compliance * Global Medical Affairs* Corporate Giving
* Healing Beyond Disease* Investors & Media
* Corporate Governance* Press Releases
* Events & Presentations * Annual Reports & Proxies* SEC Filings
* Stock Performance
* Investor FAQs
* Featured Coverage
* Careers
* Overview
* Search
* Social Media
* YouTube
NP-AT-ALL-00011119
* Cookies Statement
* Terms of Use
* Privacy Notice
* Privacy Shield Policy The site you are about to enter is intended for US healthcareprofessionals.
Please confirm you are a US healthcare professional. I am a US healthcare professional I am not a US healthcareprofessional
Amicus Therapeutics informs you that our website uses its own and third party cookies to improve our services and collect statistical information about your browsing. By clicking accept, we consider that you accept its use. For more information, or to know how to change the configuration, consult our Privacy Policy.
Accept
Privacy & Cookies PolicyClose
Necessary Always EnabledDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0